Abstract:Based on the experimental evidence that gp120 subunit vaccine did not protect individuals from HIV-1 infection, we suggested that epitope-vaccines of HIV-1 gp41 may be a new strategy to induce high levels of neutralizing antibodies against HIV-1, and characterised immunogenicity of epitope-vaccines. Two epitopes, RILAVERYLKD-epitope (aa586-596) on the N-domain and ELDKWA-epitope (aa669-674) on the C-domain of gp41, were demonstrated by us and others to induce protective activity. After vaccination course, the RILAVERYLKD-dimer epitope-vaccine [C(RILAVERYLKDG)(2)-BSA] induced strong epitope-specific antibody response by about 1:25,600 dilution, and the ELDKWA-tetramer epitope-vaccine [C-(ELDKWAG)(4)-BSA] could yet induce strong antibody response to ELDKWA-epitope by 1:12,800-25,600 dilution of antisera in mice, while rgp41 subunit vaccine induced very weak antibody response to both epitopes (1:400). In rabbit experiments, the titres of ELDKWA-epitope-specific antibody induced by ELDKWA-epitope-vaccine [C-(ELDKWAG)(4)-BSA] reached to 1:6,400, while rgp41 subunit vaccine induced very weak antibody response to this epitope and to P1 and P2 peptides (1:400). Moreover, the ELDKWA-epitope-specific antibodies in mice and rabbit antisera induced by epitope-vaccine could very strongly interact with P2 peptide sequence-corresponding to the C-domain of gp41 (dilution by 1:25,600), and the RILAVERYLKD-epitope-specific antibodies in mice antisera induced by epitope-vaccine could also very strongly interact with P1 peptide sequence-corresponding to the N-domain of gp41 (dilution by 1:102,400). All these results provided experimental evidence that epitope-vaccine may be a new general strategy to induce high levels of neutralizing antibodies against HIV-1 or other viruses.

[Characterization of the HIV-1 Subunit Vaccine Containing the Gp41 NHR Domain of the HIV-1 CRF01_AE Recombinant Subtype in China].

[Expression, Structure and Antigenicity Analysis of N51 Derived from the N-terminal Heptad Repeat Domain in Gp41 of HIV-1 CRF07_BC Strain].

Immunogenicity of DNA Vaccines Encoding Structural Proteins and Regulatory/accessory Proteins Derived from an HIV-1 CRF01_AE Isolate Circulating in China

A recombinant mimetics of the HIV-1 gp41 prehairpin fusion intermediate fused with human IgG Fc fragment elicits neutralizing antibody response in the vaccinated mice.

Immunogenicity Comparison Between Codon Optimized HIV-1 CRF BC_07 Gp140 and Gp145 Vaccines.

Construction and Immunogenicity Analysis of a Vaccine Against HIV-1 AE Recombinant

[Preparation and Characterization of Monoclonal Antibody Against Gp120 V1/V2 Domain of HIV-1 Subtype CRF01_AE].

Hiv-1 Gp41 Core with Exposed Membrane-Proximal External Region Inducing Broad Hiv-1 Neutralizing Antibodies

Induction of Neutralizing Antibody Against Human Immunodeficiency Virus Type 1 (Hiv-1) by Immunization with Gp41 Membrane-Proximal External Region (mper) Fused with Porcine Endogenous Retrovirus (perv) P15e Fragment

Expression, Purification and Characterization of Hiv-1 Capsid Precursor Protein p41

Epitope-Vaccines: A New Strategy to Induce High Levels of Neutralizing Antibodies Against Hiv-1

[Construction of Recombinant Fowlpox Virus Coexpressing Gp120 of Chinese HIV-1 Strain and IL-18 and Its Immunogenicity in Mice].

Short Communication: in VitroSynergy Between Peptides or Neutralizing Antibodies Targeting the N- and C-Terminal Heptad Repeats of HIV Type 1 Gp41

Three Candidate Peptide-Vaccines in Combination to Induce High Levels of Multiantibodies Against HIV-1

Antigenic properties of a transport-competent influenza HA/HIV Env chimeric protein.

Exploration of a Sequential Gp140-Gp145 Immunization Regimen with Heterologous Envs to Induce a Protective Cross-Reactive HIV Neutralizing Antibody Response In Non-human Primates

Peptide Design, Induction and Characterization Antibody Against Gp120 Protein

Expression, Purification, and Renaturation of a Recombinant Peptide-Based HIV Vaccine in Escherichia Coli.

Stabilized trimeric peptide immunogens of the complete HIV-1 gp41 N-heptad repeat and their use as HIV-1 vaccine candidates

Induction of High Level of Specific Antibody Response to the Neutralizing Epitope ELDKWA on HIV-1 Gp41 by Peptide-Vaccine☆

Genetic and Phenotypic Analysis of CRF01_AE HIV-1envClones from Patients Residing in Beijing, China